Manage Your Liver
Q:

What treatment options does NASH patients have?

A:

Nonalcoholic steatohepatitis or NASH is a type of non-communicable disease (NCD), also known as “lifestyle disease”. This type of disease is preventable and the most common causes are smoking, alcohol abuse, unbalanced diets and lack of physical activity.[2] NASH is similar to alcoholic liver disease, but develops in people who do not drink or drink very little alcohol. People with NASH have fat in the liver, along with inflammation and damage. If untreated, NASH may advance to cirrhosis or even liver cancer. In USA, NASH is one of the major causes of cirrhosis; statistics indicate that up to 25% of adults with NASH may have cirrhosis.

 

NASH has become more common in developed countries but its underlying cause is still not clear. It tends to occur in people who are middle-aged and overweight or obese. It is more common in women than in men. Many NASH patients have high cholesterol or triglycerides and diabetes.

 

Usually, NASH patients have few or no symptoms. Among the symptoms that do appear, fatigue, loss of appetite and weight loss for no clear reason are the most common. Because of this, most people with NASH would only discover the problem during routine checkups. By that time the disease is more advanced, making it even harder to treat. In addition, NASH patients usually have elevated ALT levels; this figure is used to determine the extent of liver damage, and can be obtained in liver function tests (LFTs).

 

Currently, there are no specific conventional treatment for NASH. Patients are generally advised to adopt a healthy lifestyle and reduce weight to normal level in order to reduce the amount of fat in the liver and improve their condition. However, there are alternative therapies that have been proven to have positive effects on NASH. [3][4][5] Patients should aim to slow or stop the progression of NASH in the early stages, and to prevent scarring of the liver and fibrosis.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
A:
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common liver diseases. They occur in people who drink little or no alcohol at all and are considered to be consequences of obesity.    However, “not obese” does not equal “no NAFLD / NASH”, since NAFLD may not be linked with obesity in some cases. Fatty liver disease may also develop in non-obese people. The terms “lean NAFLD” and “lean
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
YHK has significant effect in stopping liver inflammation; it can enhance the recovery of liver health and protect liver cells. Those who have experienced YHK often have these questions in mind: Why is YHK so different from other liver medicines and supplements? Why is it possible to have such unprecedented effects? The answer seems magical, but in fact, it is not complicated - Because YHK possesses a perfect balance.   To explain this, we must first point out that YH
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us